VC-backed Surface Oncology appoints chief scientific officer

By Iris Dorbian — 2 weeks ago

Cambridge, Massachusetts-based Surface Oncology Inc, a developer of next-generation cancer immunotherapies, has named Dr. Vito J. Palombella as chief scientific officer. Previously, Palombella worked at Infinity Pharmaceuticals where he served as executive vice president and chief scientific officer. Surface’s backers include Atlas Venture, Lilly Ventures and New Enterprise Associates.

Continue

VC-backed Aeglea BioTherapeutics promotes York to CFO

By Iris Dorbian — 5 months ago

Aeglea BioTherapeutics Inc, a biopharmaceutical company focused on treating tumor metabolism, has promoted Charles N. York to chief financial officer. Previously, York was the company’s vice president of finance and accounting. He first joined Aeglea in 2013, acting intially as a consultant before becoming a full-time employee during the summer of 2014. Aeglea’s backers include Lilly Ventures, Novartis Venture Fund, UT Horizon Fund, OrbiMed, Jennison Associates (on behalf of clients), Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group and Cowen Investments.

Continue

Aeglea Biotherapeutics snags $44 mln Series B

By Iris Dorbian — 11 months ago

Aeglea Biotherapeutics Inc, a biopharmaceutical company focused on treating tumor metabolism, has raised $44 million in Series B funding. Return backers Lilly Ventures and Novartis Venture Fund led the round with participation from other investors that included UT Horizon Fund, OrbiMed, Jennison Associates (on behalf of clients), Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group and Cowen Investments.

Continue

Nimbus Therapeutics pulls in $43 mln

By Iris Dorbian — 11 months ago

Cambridge, Massachusetts-based biotech company Nimbus Therapeutics (formerly known as Nimbus Discovery) has closed $43 million in Series B funding. Pfizer Venture Investments and Lightstone Ventures led the round with participation from the company’s previous backers that included Atlas Venture, SR One, Lilly Ventures and Bill Gates.

Continue

LTI picks up $20 mln Series A

By Iris Dorbian — 1 year ago

Cambridge, Massachusetts-based Lysosomal Therapeutics Inc, which develops molecules to treat neurodegenerative diseases, has closed $20 million in Series A funding. The backers in this round included Atlas Venture, Hatteras Venture Partners, Lilly Ventures, Sanofi-Genzyme BioVentures, Roche Venture Fund, Partners Innovation Fund and Orion Equity Partners.

Continue

Surface Oncology attracts $35 mln Series A

By Iris Dorbian — 1 year ago

Surface Oncology has secured $35 million in Series A funding. Atlas Venture, Fidelity Biosciences, Lilly Ventures and New Enterprise Associates led the round with participation from other investors that included Amgen Ventures and Novartis Institute for Biomedical Research. In addition to the funding, Dr. Elliott Sigal, former head of R&D at Bristol Myers Squibb, has been added to the company’s scientific advisory board. Based in Cambridge, Mass., Surface Oncology is a developer of next-generation cancer immunotherapies.

Continue

Symic Biomedical snags $15 mln Series A

By Iris Dorbian — 1 year ago

San Francisco-based Symic Biomedical, a healthcare-focused biotech firm, has raised $15 million in Series A funding. Lilly Ventures led the round with participation from other investors that included Den Danske Forskningsfond, Mitsui Global Investment, Ally Bridge Group, InCube Ventures, Purdue Foundry Investment Fund, Mission Bay Capital and QB3 Partners. In addition to the funding, Symic Biomedical has appointed Dr. Armen Shanafelt, a general partner at Lilly Ventures and Dr. Claus Christiansen, chairman of Nordic Biosciences, to its board of directors.

Continue

Aileron Therapeutics grabs $33 mln Series E

By Iris Dorbian — 1 year ago

Aileron Therapeutics has raised $33 million in Series E funding. The investors included AJU IB Investment Co., Apple Tree Partners, Excel Venture Management, Lilly Ventures, Novartis Venture Funds, Roche Venture Fund and SR One. Based in Cambridge, Mass., Aileron Therapeutics is a clinical stage biopharmaceutical firm that is developing therapeutics based on its proprietary Stapled Peptide drug platform.

Continue

Viamet Pharma raises $60 mln

By Luisa Beltran — 1 year ago

Viamet Pharmaceuticals Holdings said Tuesday it closed a $60 million Series D financing provided by Brandon Point Industries Ltd. working with Woodford Investment Management. Current investors includes Novartis Venture Fund, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners, Lurie Holdings and Astellas Venture Management. Durham, N.C.-based Viamet Pharma develops antifungal agents using a metalloenzyme medicinal chemistry platform.

Continue

Coherus BioSciences nabs $55 mln Series C

By Iris Dorbian — 2 years ago

Coherus BioSciences has raised $55 million in Series C funding. The investors included KKR, Venrock, RA Capital Management, Rock Springs Capital, Fidelity Biosciences, Sofinnova Ventures, Lilly Ventures and Vivo Capital. Based in Redwood City, Calif., Coherus BioSciences is a biologics platform focused on biosimilars.

Continue

Atlas Venture leads seed round for Lysosomal Therapeutics

By Iris Dorbian — 2 years ago

Lysosomal Therapeutics has secured $4.8 million in seed funding. Atlas Venture led the round with participation from Hatteras Venture Partners, Lilly Ventures, Sanofi-Genzyme BioVentures, Roche Venture Fund, Partners Innovation Fund and Orion Equity Partners. Headquartered in Cambridge, Mass., Lysosomal Therapeutics develops molecules to be used to treat neurodegenerative diseases.

Continue

Nimbus Discovery Names Lynch Executive Chairman

By Angela Sormani — 3 years ago

Biotechnology company Nimbus Discovery has appointed Daniel Lynch has been appointed to the company’s board of directors as executive chairman. Lynch will succeed Bruce Booth, D. Phil., partner at Atlas Venture and co-founder of Nimbus, who will remain on the board. Nimbus is backed by life science investors including Atlas Venture, SR One, Lilly Ventures and Gates Ventures.

Continue

Sutro Biopharma Secures More Funds Led by Skyline Ventures

By Angela Sormani — 4 years ago

San Francisco-based Sutro Biopharma has closed a $16.5 million second tranche of its Series C financing. The financing was led by Skyline Ventures and included participation of Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta Partners. Sutro has raised almost $60 million since its founding in 2003. PRESS RELEASE Sutro Biopharma today announced the […]

Continue

Cerulean Pharma Closes Series D

By Angela Sormani — 4 years ago

Cerulean Pharma, a developer of nanopharmaceuticals, has closed a $15 million Series D financing with participation from new investor, CVF, an affiliate of Henry Crown and Company of Chicago, Illinois, as well as full participation from all other existing investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, and Bessemer Venture Partners. Cerulean’s offices […]

Continue

Nimbus Discovery Inks $24M Series A

5 years ago

Biopharma company Nimbus Discovery has closed on a $24 million Series A round co-led by Atlas Venture, SR One, and Lilly Ventures. Existing investor, Bill Gates, also participated, the company said. Nimbus uses computational technology to discover medicines for difficult-to-drug diseases, and will use the infusion of capital to accelerate its existing development programs. The company closed on an undisclosed amount of seed financing in March.

Continue

FORMA Therapeutics Raises $25.5 Million

By PEHub Administrator — 6 years ago

FORMA Therapeutics, a Cambridge, Mass.-based small molecule drug developer with an initial focus on cancer, has raised $25.5 million in Series B funding. Lilly Ventures led the round, and was joined by return backers Novartis Option Fund and Bio*One Capital. The company previously raised $25 million.

Continue